Infinity Property and Casualty (IPCC) Analysts See $1.67 EPS; Shorts at Trillium Therapeutics (TRIL) Raised By 14.85%

February 19, 2018 - By Nellie Frank

Trillium Therapeutics Incorporated (NASDAQ:TRIL) had an increase of 14.85% in short interest. TRIL’s SI was 292,300 shares in February as released by FINRA. Its up 14.85% from 254,500 shares previously. With 173,300 avg volume, 2 days are for Trillium Therapeutics Incorporated (NASDAQ:TRIL)’s short sellers to cover TRIL’s short positions. The SI to Trillium Therapeutics Incorporated’s float is 4.46%. The stock decreased 2.04% or $0.15 during the last trading session, reaching $7.2. About 76,885 shares traded. Trillium Therapeutics Inc. (NASDAQ:TRIL) has declined 39.86% since February 19, 2017 and is downtrending. It has underperformed by 56.56% the S&P500.

Analysts expect Infinity Property and Casualty Corporation (NASDAQ:IPCC) to report $1.67 EPS on February, 27.They anticipate $0.17 EPS change or 9.24% from last quarter’s $1.84 EPS. IPCC’s profit would be $18.21M giving it 18.25 P/E if the $1.67 EPS is correct. After having $1.38 EPS previously, Infinity Property and Casualty Corporation’s analysts see 21.01% EPS growth. The stock increased 3.52% or $4.15 during the last trading session, reaching $121.9. About 308,016 shares traded or 230.41% up from the average. Infinity Property and Casualty Corporation (NASDAQ:IPCC) has risen 25.56% since February 19, 2017 and is uptrending. It has outperformed by 8.86% the S&P500.

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company has market cap of $93.51 million. The companyÂ’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. It currently has negative earnings. The Company’s product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase.

Among 3 analysts covering Trillium Therapeutics (NASDAQ:TRIL), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Trillium Therapeutics had 5 analyst reports since August 26, 2015 according to SRatingsIntel. The company was maintained on Thursday, June 8 by Ladenburg. The stock has “Buy” rating by Cowen & Co on Wednesday, July 5. The company was upgraded on Wednesday, August 26 by Zacks. H.C. Wainwright maintained the shares of TRIL in report on Thursday, December 14 with “Buy” rating.

Among 2 analysts covering Infinity Property and Casualty (NASDAQ:IPCC), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Infinity Property and Casualty had 10 analyst reports since September 16, 2015 according to SRatingsIntel. The stock of Infinity Property and Casualty Corporation (NASDAQ:IPCC) earned “Market Outperform” rating by JMP Securities on Wednesday, September 16. On Friday, January 20 the stock rating was downgraded by Raymond James to “Mkt Perform”. As per Thursday, December 21, the company rating was maintained by Keefe Bruyette & Woods. The company was maintained on Wednesday, September 20 by Keefe Bruyette & Woods. Raymond James upgraded the shares of IPCC in report on Thursday, July 13 to “Outperform” rating. As per Tuesday, February 13, the company rating was maintained by Keefe Bruyette & Woods. The firm has “Mkt Perform” rating given on Tuesday, November 1 by Keefe Bruyette & Woods. The firm has “Hold” rating by Keefe Bruyette & Woods given on Monday, December 4.

Infinity Property and Casualty Corporation, through its subsidiaries, provides personal automobile insurance products in the United States. The company has market cap of $1.33 billion. The firm offers nonstandard automobile, commercial vehicle, and classic collector automobile insurance products. It has a 29.73 P/E ratio. It also provides reinsurance services and products.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: